LPCN Valuation

Lipocine Inc

Add to Watchlist

Advanced Chart

2.910

-0.07(-2.349%)1D

Overview
Forecast
Valuation
Earnings

LPCN Relative Valuation

LPCN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LPCN is overvalued; if below, it's undervalued.

Historical Valuation

Lipocine Inc (LPCN) is now in the Overvalued zone, suggesting that its current forward PS ratio of 24.02 is considered Overvalued compared with the five-year average of -5.07. The fair price of Lipocine Inc (LPCN) is between 0.68 to 2.08 according to relative valuation methord. Compared to the current price of 2.89 USD , Lipocine Inc is Overvalued By 39.13%.

Relative Value

Fair Zone

0.68-2.08

Current Price：2.89

39.13%

Overvalued

-1.33

Trailing

Forward

0.00

EV/EBITDA

Lipocine Inc. (LPCN) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.08. The thresholds are as follows: Strongly Undervalued below -0.47, Undervalued between -0.47 and -0.19, Fairly Valued between 0.36 and -0.19, Overvalued between 0.36 and 0.63, and Strongly Overvalued above 0.63. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.13

EV/EBIT

Lipocine Inc. (LPCN) has a current EV/EBIT of 0.13. The 5-year average EV/EBIT is -2.10. The thresholds are as follows: Strongly Undervalued below -9.85, Undervalued between -9.85 and -5.97, Fairly Valued between 1.77 and -5.97, Overvalued between 1.77 and 5.65, and Strongly Overvalued above 5.65. The current Forward EV/EBIT of 0.13 falls within the Historic Trend Line -Fairly Valued range.

23.78

Lipocine Inc. (LPCN) has a current PS of 23.78. The 5-year average PS is 15.43. The thresholds are as follows: Strongly Undervalued below -20.86, Undervalued between -20.86 and -2.72, Fairly Valued between 33.57 and -2.72, Overvalued between 33.57 and 51.72, and Strongly Overvalued above 51.72. The current Forward PS of 23.78 falls within the Historic Trend Line -Fairly Valued range.

-1.76

P/OCF

Lipocine Inc. (LPCN) has a current P/OCF of -1.76. The 5-year average P/OCF is -7.03. The thresholds are as follows: Strongly Undervalued below -31.33, Undervalued between -31.33 and -19.18, Fairly Valued between 5.11 and -19.18, Overvalued between 5.11 and 17.26, and Strongly Overvalued above 17.26. The current Forward P/OCF of -1.76 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Lipocine Inc. (LPCN) has a current P/FCF of 0.00. The 5-year average P/FCF is 5.00. The thresholds are as follows: Strongly Undervalued below -36.16, Undervalued between -36.16 and -15.58, Fairly Valued between 25.58 and -15.58, Overvalued between 25.58 and 46.16, and Strongly Overvalued above 46.16. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Lipocine Inc (LPCN) has a current Price-to-Book (P/B) ratio of 0.93. Compared to its 3-year average P/B ratio of 1.03 , the current P/B ratio is approximately -9.08% higher. Relative to its 5-year average P/B ratio of 2.16, the current P/B ratio is about -56.77% higher. Lipocine Inc (LPCN) has a Forward Free Cash Flow (FCF) yield of approximately -31.12%. Compared to its 3-year average FCF yield of -33.80%, the current FCF yield is approximately -7.93% lower. Relative to its 5-year average FCF yield of -24.76% , the current FCF yield is about 25.68% lower.

0.91

P/B

Median3y

1.03

Median5y

2.16

-31.44

FCF Yield

Median3y

-33.80

Median5y

-24.76

Competitors Valuation Multiple

The average P/S ratio for LPCN's competitors is 3.96, providing a benchmark for relative valuation. Lipocine Inc Corp (LPCN) exhibits a P/S ratio of 23.78, which is 500.00% above the industry average. Given its robust revenue growth of 595.42%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Minerva Neurosciences Inc

Loss

16.50M

MBRX.O

Moleculin Biotech Inc

Loss

11.88M

HOTH.O

Hoth Therapeutics Inc

Loss

15.38M

NEUP.O

Neuphoria Therapeutics Inc

Loss

21.30M

Performance Decomposition

Market capitalization of LPCN decreased by 18.80% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 89.57K to 622.85K.

The secondary factor is the Margin Expansion, contributed -89.66%to the performance.

Overall, the performance of LPCN in the past 1 year is driven by Revenue Growth. Which is more sustainable.

595.42%

89.57K → 622.85K

Revenue Growth

-89.66%

-3.43K → -354.13

Margin Expansion

-524.56%

0.81 → -3.45

P/E Change

-18.80%